Search

Your search keyword '"D'Inca F"' showing total 8 results
Start Over Author "D'Inca F" Language english
8 results on '"D'Inca F"'

6. P1.01-53 Bone Metastases and Efficacy of Immunotherapy in Patients with Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Author

Landi, L., D'Incà, F., Cortesi, E., Chiari, R., Grossi, F., Delmonte, A., De Marinis, F., Signorelli, D., Dazzi, C., Sperandi, F., Catino, A., Giannarelli, D., Soto Parra, H., Minuti, G., Bordi, P., Migliorino, M.R., Palla, A., Tonini, G., Cognetti, F., Santoro, A., Tassinari, D., Scoppola, A., Bidoli, P., Piantedosi, F., Maio, M., Crinò, L., and Cappuzzo, F.

Published
2018
Full Text
View/download PDF

7. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

Author

Lorenza Landi, Antonio Passaro, Rita Chiari, Francesco Grossi, Marcello Tiseo, Paolo Bidoli, Luca Toschi, Angelo Delmonte, Hector Soto Parra, Luana Calabrò, Diego Signorelli, Francesco Gelsomino, Diana Giannarelli, Francovito Piantedosi, F. D'Incà, Federico Cappuzzo, Domenico Galetta, Alain Gelibter, Gabriele Minuti, Maria Rita Migliorino, Francesco Cognetti, Landi, L, D'Inca, F, Gelibter, A, Chiari, R, Grossi, F, Delmonte, A, Passaro, A, Signorelli, D, Gelsomino, F, Galetta, D, Giannarelli, D, Soto Parra, H, Minuti, G, Tiseo, M, Migliorino, M, Cognetti, F, Toschi, L, Bidoli, P, Piantedosi, F, Calabro', L, and Cappuzzo, F

Subjects
0301 basic medicine, Oncology, Male, Cancer Research, Lung Neoplasms, Cohort Studies, 0302 clinical medicine, Antineoplastic Agents, Immunological, Carcinoma, Non-Small-Cell Lung, 80 and over, Immunology and Allergy, Medicine, Molecular Targeted Therapy, Prospective cohort study, Non-Small-Cell Lung, Aged, 80 and over, Clinical Trials as Topic, Tumor, Bone metastasis, Bone metastases, Immunotherapy, Nivolumab, Non-small-cell lung cancer, PD-L1, Adult, Aged, Biomarkers, Tumor, Bone Neoplasms, Female, Humans, Middle Aged, Prognosis, Treatment Outcome, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Immunological, 030220 oncology & carcinogenesis, Cohort, Molecular Medicine, Research Article, Cohort study, medicine.medical_specialty, Immunology, Antineoplastic Agents, lcsh:RC254-282, 03 medical and health sciences, Internal medicine, Progression-free survival, Lung cancer, Pharmacology, Performance status, business.industry, Carcinoma, medicine.disease, Bone metastase, 030104 developmental biology, Expanded access, business, Biomarkers
Abstract

Background Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy. Methods Pretreated non-squamous (cohort A) and squamous (cohort B) NSCLCs included in the Italian Expanded Access Program were evaluated for nivolumab efficacy according to BoM. Results Cohort A accounted for 1588 patients with non-squamous NSCLC, including 626 (39%) with (BoM+) and 962 (61%) without BoM (BoM-). Cohort B accounted for 371 patients with squamous histology including 120 BoM+ (32%) and 251 (68%) BoM- cases. BoM+ had lower overall response rate (ORR; Cohort A: 12% versus 23%, p

Published
2019

8. Mast cell: an emerging partner in immune interaction.

Author

Gri G, Frossi B, D'Inca F, Danelli L, Betto E, Mion F, Sibilano R, and Pucillo C

Abstract

Mast cells (MCs) are currently recognized as effector cells in many settings of the immune response, including host defense, immune regulation, allergy, chronic inflammation, and autoimmune diseases. MC pleiotropic functions reflect their ability to secrete a wide spectrum of preformed or newly synthesized biologically active products with pro-inflammatory, anti-inflammatory and/or immunosuppressive properties, in response to multiple signals. Moreover, the modulation of MC effector phenotypes relies on the interaction of a wide variety of membrane molecules involved in cell-cell or cell-extracellular-matrix interaction. The delivery of co-stimulatory signals allows MC to specifically communicate with immune cells belonging to both innate and acquired immunity, as well as with non-immune tissue-specific cell types. This article reviews and discusses the evidence that MC membrane-expressed molecules play a central role in regulating MC priming and activation and in the modulation of innate and adaptive immune response not only against host injury, but also in peripheral tolerance and tumor-surveillance or -escape. The complex expression of MC surface molecules may be regarded as a measure of connectivity, with altered patterns of cell-cell interaction representing functionally distinct MC states. We will focalize our attention on roles and functions of recently discovered molecules involved in the cross-talk of MCs with other immune partners.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results